192 related articles for article (PubMed ID: 20197390)
1. Molecular pharmacology and antitumor activity of PHT-427, a novel Akt/phosphatidylinositide-dependent protein kinase 1 pleckstrin homology domain inhibitor.
Meuillet EJ; Zuohe S; Lemos R; Ihle N; Kingston J; Watkins R; Moses SA; Zhang S; Du-Cuny L; Herbst R; Jacoby JJ; Zhou LL; Ahad AM; Mash EA; Kirkpatrick DL; Powis G
Mol Cancer Ther; 2010 Mar; 9(3):706-17. PubMed ID: 20197390
[TBL] [Abstract][Full Text] [Related]
2. 3-Phosphoinositide-dependent kinase 1 potentiates upstream lesions on the phosphatidylinositol 3-kinase pathway in breast carcinoma.
Maurer M; Su T; Saal LH; Koujak S; Hopkins BD; Barkley CR; Wu J; Nandula S; Dutta B; Xie Y; Chin YR; Kim DI; Ferris JS; Gruvberger-Saal SK; Laakso M; Wang X; Memeo L; Rojtman A; Matos T; Yu JS; Cordon-Cardo C; Isola J; Terry MB; Toker A; Mills GB; Zhao JJ; Murty VV; Hibshoosh H; Parsons R
Cancer Res; 2009 Aug; 69(15):6299-306. PubMed ID: 19602588
[TBL] [Abstract][Full Text] [Related]
3. Pleckstrin homology domain of Akt kinase: a proof of principle for highly specific and effective non-enzymatic anti-cancer target.
Joh EH; Hollenbaugh JA; Kim B; Kim DH
PLoS One; 2012; 7(11):e50424. PubMed ID: 23189201
[TBL] [Abstract][Full Text] [Related]
4. A Novel Inhibitor of AKT1-PDPK1 Interaction Efficiently Suppresses the Activity of AKT Pathway and Restricts Tumor Growth In Vivo.
Mäemets-Allas K; Viil J; Jaks V
Mol Cancer Ther; 2015 Nov; 14(11):2486-96. PubMed ID: 26294745
[TBL] [Abstract][Full Text] [Related]
5. Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1.
Feldman RI; Wu JM; Polokoff MA; Kochanny MJ; Dinter H; Zhu D; Biroc SL; Alicke B; Bryant J; Yuan S; Buckman BO; Lentz D; Ferrer M; Whitlow M; Adler M; Finster S; Chang Z; Arnaiz DO
J Biol Chem; 2005 May; 280(20):19867-74. PubMed ID: 15772071
[TBL] [Abstract][Full Text] [Related]
6. In vivo molecular pharmacology and antitumor activity of the targeted Akt inhibitor PX-316.
Meuillet EJ; Ihle N; Baker AF; Gard JM; Stamper C; Williams R; Coon A; Mahadevan D; George BL; Kirkpatrick L; Powis G
Oncol Res; 2004; 14(10):513-27. PubMed ID: 15559765
[TBL] [Abstract][Full Text] [Related]
7. Remimazolam attenuates inflammation in bronchopneumonia through the inhibition of NLRP3 activity by PDPK1 ubiquitination.
Yang M; Li L
Chem Biol Drug Des; 2024 Jan; 103(1):e14438. PubMed ID: 38230783
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of Akt kinase activity by a peptide spanning the betaA strand of the proto-oncogene TCL1.
Hiromura M; Okada F; Obata T; Auguin D; Shibata T; Roumestand C; Noguchi M
J Biol Chem; 2004 Dec; 279(51):53407-18. PubMed ID: 15459205
[TBL] [Abstract][Full Text] [Related]
9. BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling-dependent tumor growth in mouse models.
Politz O; Siegel F; Bärfacker L; Bömer U; Hägebarth A; Scott WJ; Michels M; Ince S; Neuhaus R; Meyer K; Fernández-Montalván AE; Liu N; von Nussbaum F; Mumberg D; Ziegelbauer K
Int J Cancer; 2017 Jan; 140(2):449-459. PubMed ID: 27699769
[TBL] [Abstract][Full Text] [Related]
10. AT7867 is a potent and oral inhibitor of AKT and p70 S6 kinase that induces pharmacodynamic changes and inhibits human tumor xenograft growth.
Grimshaw KM; Hunter LJ; Yap TA; Heaton SP; Walton MI; Woodhead SJ; Fazal L; Reule M; Davies TG; Seavers LC; Lock V; Lyons JF; Thompson NT; Workman P; Garrett MD
Mol Cancer Ther; 2010 May; 9(5):1100-10. PubMed ID: 20423992
[TBL] [Abstract][Full Text] [Related]
11. Tirucallic acids are novel pleckstrin homology domain-dependent Akt inhibitors inducing apoptosis in prostate cancer cells.
Estrada AC; Syrovets T; Pitterle K; Lunov O; Büchele B; Schimana-Pfeifer J; Schmidt T; Morad SA; Simmet T
Mol Pharmacol; 2010 Mar; 77(3):378-87. PubMed ID: 20018812
[TBL] [Abstract][Full Text] [Related]
12. Discovery of a novel class of AKT pleckstrin homology domain inhibitors.
Mahadevan D; Powis G; Mash EA; George B; Gokhale VM; Zhang S; Shakalya K; Du-Cuny L; Berggren M; Ali MA; Jana U; Ihle N; Moses S; Franklin C; Narayan S; Shirahatti N; Meuillet EJ
Mol Cancer Ther; 2008 Sep; 7(9):2621-32. PubMed ID: 18790745
[TBL] [Abstract][Full Text] [Related]
13. Sensitizing estrogen receptor-negative breast cancer cells to tamoxifen with OSU-03012, a novel celecoxib-derived phosphoinositide-dependent protein kinase-1/Akt signaling inhibitor.
Weng SC; Kashida Y; Kulp SK; Wang D; Brueggemeier RW; Shapiro CL; Chen CS
Mol Cancer Ther; 2008 Apr; 7(4):800-8. PubMed ID: 18413793
[TBL] [Abstract][Full Text] [Related]
14. A small molecule inhibits Akt through direct binding to Akt and preventing Akt membrane translocation.
Kim D; Sun M; He L; Zhou QH; Chen J; Sun XM; Bepler G; Sebti SM; Cheng JQ
J Biol Chem; 2010 Mar; 285(11):8383-94. PubMed ID: 20068047
[TBL] [Abstract][Full Text] [Related]
15. Phosphatidylinositol ether lipid analogues induce AMP-activated protein kinase-dependent death in LKB1-mutant non small cell lung cancer cells.
Memmott RM; Gills JJ; Hollingshead M; Powers MC; Chen Z; Kemp B; Kozikowski A; Dennis PA
Cancer Res; 2008 Jan; 68(2):580-8. PubMed ID: 18199555
[TBL] [Abstract][Full Text] [Related]
16. PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity.
Yuan J; Mehta PP; Yin MJ; Sun S; Zou A; Chen J; Rafidi K; Feng Z; Nickel J; Engebretsen J; Hallin J; Blasina A; Zhang E; Nguyen L; Sun M; Vogt PK; McHarg A; Cheng H; Christensen JG; Kan JL; Bagrodia S
Mol Cancer Ther; 2011 Nov; 10(11):2189-99. PubMed ID: 21750219
[TBL] [Abstract][Full Text] [Related]
17. Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers.
Coussy F; El Botty R; Lavigne M; Gu C; Fuhrmann L; Briaux A; de Koning L; Dahmani A; Montaudon E; Morisset L; Huguet L; Sourd L; Painsec P; Chateau-Joubert S; Larcher T; Vacher S; Melaabi S; Salomon AV; Marangoni E; Bieche I
J Hematol Oncol; 2020 Feb; 13(1):13. PubMed ID: 32087759
[TBL] [Abstract][Full Text] [Related]
18. Specific inhibition of the Akt1 pleckstrin homology domain by D-3-deoxy-phosphatidyl-myo-inositol analogues.
Meuillet EJ; Mahadevan D; Vankayalapati H; Berggren M; Williams R; Coon A; Kozikowski AP; Powis G
Mol Cancer Ther; 2003 Apr; 2(4):389-99. PubMed ID: 12700283
[TBL] [Abstract][Full Text] [Related]
19. Genetic alterations in the phosphoinositide 3-kinase/Akt signaling pathway confer sensitivity of thyroid cancer cells to therapeutic targeting of Akt and mammalian target of rapamycin.
Liu D; Hou P; Liu Z; Wu G; Xing M
Cancer Res; 2009 Sep; 69(18):7311-9. PubMed ID: 19706758
[TBL] [Abstract][Full Text] [Related]
20. Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt.
Yang L; Dan HC; Sun M; Liu Q; Sun XM; Feldman RI; Hamilton AD; Polokoff M; Nicosia SV; Herlyn M; Sebti SM; Cheng JQ
Cancer Res; 2004 Jul; 64(13):4394-9. PubMed ID: 15231645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
